This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Royalty Pharma AG
Drug Names(s): dapoxetine hydrochloride
Description: Dapoxetine is a selective serotonin reuptake inhibitor (SSRI). As a member of the well-known SSRI class of compounds, dapoxetine would become the first oral pharmacologic product indicated for the treatment of premature ejaculation, pending approval. Premature ejaculation is the most common form of male sexual dysfunction, affecting up to thirty percent of men in the United States.
Furiex and ALZA/Janssen
Alza, a subsidiary of Johnson & Johnson, licensed Dapoxetine from PPD. Alza received worldwide rights to develop and commercialize Dapoxetine and bears the responsibility for manufacturing, regulatory, and marketing costs.
In May 2012, Furiex announced that it entered into an agreement with ALZA and Janssen whereby ALZA and Janssen will transfer worldwide rights for Priligy to Furiex. Janssen will continue to manufacture and manage certain clinical and regulatory activities with respect to Priligy for a pre-defined period after the closing date of the agreement. Janssen will continue to make Priligy available to patients until the Marketing Authorizations are transferred, at which time commercialization of the product will transition to Furiex or its licensee.
Under the agreement, Janssen will transfer to Furiex registration and commercialization activities for Priligy worldwide. Janssen will remain the Marketing Authorization...See full deal structure in Biomedtracker
Partners: The Menarini Group Eli Lilly & Company Johnson & Johnson
Additional information available to subscribers only: